Introduction

The term follow-up refers to the timely surveillance of health status and guidance on a medication regimen for patients who have been treated by medical staff through a variety of methods [1]. It is now well accepted that follow-up plays an irreplaceable role in chronic disease management, detecting complications associated with a surgery, collection outcome data and diagnosis of recurrent disease [2-5]. Increasing numbers of studies have reported that the treatment effect and prognosis of disease are significantly related to adherence to follow-up (AFU), including studies of coronary artery diseases [2], cerebral infarction [6]. Diabetes [7], asthma [8], chronic kidney disease [3], obesity [9], chronic sinusitis [10], cataract [11], and amblyopia [12]. In addition to the treatment effect [13], AFU can seriously affect clinical research, such as by undermining the internal and external validity of the findings and causing bias, increasing the cost or duration of the trial or delaying important results [14].

However, the measurement of AFU varies in different studies, and there is still a lack of research focusing on standardizing methods for calculating AFU. Moreover, various influencing factors of AFU have been reported in different studies, in which different intervention strategies for AFU were used. The increasing variety of measurement, associated factors and intervention strategies of AFU existing in published studies reflect an increasing awareness of the importance of AFU by clinical investigators. Gaining a systematic understanding of these considerations will be an important step in improving the quality of clinical research. As we previously reported, mobile information technology, short message service (SMS) and telephone included could significantly improve FUR [15]. However, to our knowledge, there is still no systematic review addressing this goal. In the present study, we aimed to systematically assess the meaning of AFU, evaluate the measurement methods used in previous studies, identify influencing factors associated with AFU and explore effective intervention improvements, which would offer guidance in development directions to improve patient AFU.

Methods

Literature sources

A comprehensive search of databases from January 1995 to
February 2014, including Medline, EMBASE, PubMed, and the Cochrane Library, was conducted using the combined following key words searched in the title or abstract: "follow-up"; "adherence" or "compliance"; "clinical research"; "measurement", "follow-up rate" "factors" or "intervention". These databases were selected because they were considered to contain a high proportion of widely read and practice-changing clinical studies covering a broad range of medical aspects. We also searched conference abstracts and the reference lists of the studies identified by the search. Only English-language journal articles or those with English abstracts containing adequate information to be extracted were included. Two authors independently screened titles and abstracts to determine potential eligibility for this systematic review. When screening discrepancies occurred, consensus was achieved after further discussion.

Inclusion and exclusion criteria
We carefully reviewed all potentially relevant articles that included studies of measurement, associated factors and intervention strategies of AFU. The inclusion of the studies was not restricted to study design ranging from observational study (retrospective and prospective included) to randomized controlled study, relevant comments and reviews are also included to achieve a better coverage. The studied patients or population size were not restricted. For the studies relevant to measurement to AFU, specific AFU calculation formula or measurement strategy should be mentioned to be included; The eligible articles concerning associated factors and intervention strategies of AFU should have collected or statistical data to indicate direction and magnitude of associated factors or intervention strategies to AFU, so as to guarantee methodological rigor and validity of this study. Studies with duplicate data were excluded, and the newest and most informative article was selected when multiple studies were conducted by the same authors.

Date extraction and outcome measure
Adhering to the international systematic review guidance of the Cochrane Collaboration, the data from each eligible study were extracted independently by two reviewers to rule out subjectivity in the data gathering and entry processes. The extracted data were independently recorded into separate databases by both investigators. The two completed databases were compared and discussed between the two investigators until a consensus was reached. We did not contact the authors of the eligible studies for additional data. The included studies of measurement, associated factors and intervention strategies of AFU were classified into major categories and sub-categories. Intervention strategies to promote AFU were also classified, calculated and analyzed. Diversity in category and sub-category strategies for each part can mostly be explained by the differences in the collected information from included studies, and the innate nature for each item. 6 methods for measurement of AFU are derived according to definition of follow-up, ranging from a consultation with a physician to completion of all recommended testing or diagnostic resolution. Category method for intervention strategies was consistent with the major aspects of associated factors, however less items were listed than the latter, for the included study appeared in smaller number and more focused research objectives. Associated study number for each sub-category was counted respectively. Total numbers for the major categories were calculated considering the overlap for the subcategories among the studies, for instance, a study which talked of age as an associated factor will possibly mention sex, or education, meanwhile. All statistical analyses were performed using the software SPSS version 17 (SPSS Inc., Chicago, IL, USA).

Results
Study selection
Of the 12359 articles initially identified, 18 articles were excluded because they were duplicate publications. After screening the titles and abstracts, an additional 11974 articles were excluded. The remaining 367 articles were reviewed in full text. After the full text review, 242 articles were excluded because they did not involve AFU. At the end of this culling process, 125 articles were selected for the systemic review. Figure 1 shows a flow diagram of the selection process for the relevant studies.

Study characteristics
The number of published studies that were related to AFU showed a significant increasing trend from 47 studies during 1995–2004 to 78 studies during the last decade. The study types that
were included consisted of 36 reviews, 35 observational studies, 32 randomized controlled trials, 17 retrospective studies, 4 comments and 1 prospective study. The included studies originated from the United States (85), Europe (22), Asia (8), Australia (8) and Canada (2). Providing great diversity in study design for the studies included, together with the purpose to illuminate different aspects of considerations for AFU, the present systematic review was performed.

**Quantitative measurements of AFU**

The follow-up rate (FUR) was the most widely accepted and recognized measurement index of AFU, while attendance rate, retesting rate and screen rate were also identified in various research backgrounds. Six different calculation methods were identified in the included studies (Table 1). FURs were identified in the majority of studies (123/125); although the numerators varied, all shared the same denominator. Only two studies marked the FUR with a corresponding “time label”; for a clinical trial in which outcome data will be collected at different time points, the corresponding FUR should be given at the same time.

**Factors associated with AFU**

The factors associated with AFU that were identified in our included studies were classified into 5 major categories: individual patient characteristics, social supports, medical staff characteristics, research design and practice setting and public health care policy. Each of these major categories was subcategorized into 12, 3, 7, 5 and 3 subcategories, respectively (Table 2). The factor of “individual patient characteristics”, “research design and practice setting” were most studied, with respect to having the most subcategories (12) and most related studies (76/125) respectively.

**Intervention strategies to promote AFU**

In the included studies, the intervention strategies that were designed to promote AFU were classified into 3 major categories: patient and family support management, information system and interaction improvement and research design enhancement. Each of these categories was subcategorized into 4, 3 and 3 subcategories, respectively (Table 3). Information system and interaction improvement was the most studied intervention strategy (56/99), and research design enhancement was the least studied.

**Discussion**

Clinical trials differ from laboratory studies in that clinical trials involve human beings, who usually require follow-up at different time points to collect information for the study objectives [16]. Therefore, the AFU of the participants seriously affects the implementation of clinical research [17], can undermine the internal and external validity of the findings and can cause bias. Participant loss to follow-up usually necessitates higher participant enrollments to attain adequate power for valid trial results. Higher enrollments may increase the cost or duration of trials or delay important results [16]. In our present systematic review, we provided a systematic review of the measurements, associated factors and intervention strategies of AFU, offering guidance in development directions to improve patient AFU, which is an important step toward improving the quality of clinical research.

Most of the published “follow-up” studies measured patient AFU, but the calculation methods differed according to the definition of “follow-up” and ranged from a consultation with a physician to the completion of all recommended tests and diagnostic resolution. In the present study, we identified six different calculation methods of AFU. Although, the majority of studies used FURs, here we emphasize and discuss the last two of these methods. Conventionally, patient loss to follow-up accumulates over time. A prospective, controlled Swedish study of obese subjects aimed to evaluate the persistent effect of bariatric surgery on lifestyle and metabolic and cardiovascular risk after 2 and 10 years; the follow-up rates for the laboratory examinations were reported as 86.6 percent at 2 years and 74.5 percent at 10 years [18]. In a prostate cancer study, 176 of 187 eligible patients had records available for follow-up (follow-up rate: 94%), but only 52 patients were followed for more than 10 years (follow-up rate: 30%) [19]. For multiple calculations, a study compared the measurement of complete diagnostic evaluations after a positive fecal occult blood test by utilizing external chart review, internal chart audit, administrative data review and a combination of chart and administrative data review. Depending on the methods used to obtain different measurements, the patient rates of receiving diagnostic tests ranged from 44 percent to 56 percent [20]. Yet one limitation should be emphasized here when evaluating the measurements of AFU. The relevant articles included in the systematic review are restricted to studies which mainly focus on measurement, associated factors and intervention strategies of AFU. However, each clinical research displays its own image in the area of follow-up, which makes it a complexity. For example, for a long term follow-up study, a randomized individual possibly has reached a time point before he has the chance of loss to follow-up [21]. It is entirely consistent with follow-up for vital status in cancer trials, while contributes to underestimation of probability of loss to follow-up. Further detail studies remains to be seen. In addition to the six quantitative calculation methods of AFU that are presented in Table 1, AFU was also qualitatively evaluated with six follow-up scales. Qualitative evaluation is often observed in studies that are designed to evaluate the influence of AFU on treatment efficacy.

**Table 1: Calculation methods of AFU.**

| Index defined                  | Calculation methods                                                                 | Studies |
|-------------------------------|------------------------------------------------------------------------------------|---------|
| Follow-up rate                | Number of patients completing recommended follow-up + Number of eligible patients enrolled | 30      |
| Follow-up rate                | Number of patients completing all, some or none of the appropriate follow-up + Number of eligible patients enrolled | 54      |
| Follow-up rate                | Number of patients with at least one additional test + Number of eligible patients enrolled | 33      |
| Timely follow-up rate         | Number of patients completing follow-up at different time-points + Number of eligible patients enrolled | 6       |
| Multiple calculations         | Compared measurements by external chart review, internal chart audit, administrative data review and a combination of chart review and administrative data review | 2       |
Table 2: Factors associated with AFU.

| Major Category                        | Subcategory                                                                 | Studies |
|---------------------------------------|-----------------------------------------------------------------------------|---------|
| 1. Individual Patient Characteristics | Socioeconomic status                                                      | 5       |
|                                       | Difficult access to care                                                   | 5       |
|                                       | Lack of insurance                                                          | 3       |
|                                       | Race                                                                        | 5       |
|                                       | Age                                                                         | 21      |
|                                       | Gender                                                                      | 14      |
|                                       | Education level                                                            | 11      |
|                                       | Marital status                                                             | 8       |
|                                       | Functional impairment                                                      | 3       |
|                                       | Lack of transportation and child care                                      | 6       |
|                                       | Knowledge and understanding of the research (fear and coping)               | 6       |
|                                       | Health status (pregnancy, HIV status, addiction, domestic violence, cognitive performance, verbal intelligence and comorbidities) | 4       |
| Total                                 |                                                                             | 54      |
| 2. Social Support                     | Family support                                                             | 6       |
|                                       | Friend support                                                             | 4       |
|                                       | Healthcare provider support                                                | 5       |
| Total                                 |                                                                             | 12      |
| 3. Medical Staff Characteristics      | Physician-patient communication (regarding risk, medication choice, results and necessary follow-up) | 13      |
|                                       | Communication among providers                                              | 8       |
|                                       | Transparency of the informed consent document                              | 1       |
|                                       | Relationship among the study coordinator, care providers and participants   | 9       |
|                                       | Consistency in protocols for maintaining contact with participants          | 2       |
|                                       | Failure to refer for further testing                                       | 3       |
|                                       | Physician’s lack of adherence to guidelines                                 | 1       |
| Total                                 |                                                                             | 28      |
| 4. Research Design and Practice Setting| "Control group” attrition                                                  | 1       |
|                                       | Therapy-related factors (route of administration, complexity of treatment, duration of treatment period, side effects of medication, degree of required behavioral change, taste of medication and requirements for drug storage) | 26      |
|                                       | Reminder system                                                            | 39      |
|                                       | Organizational structural characteristics (waiting times, on-site specialists and technology options) | 7       |
|                                       | Case managers or navigators                                                 | 3       |
| Total                                 |                                                                             | 76      |
| 5. Public Health Care Policy          | Professional norms                                                         | 2       |
|                                       | Evidence-based guidelines for follow-up diagnosis                          | 1       |
|                                       | Quality expectations and benchmarks                                         | 1       |
| Total                                 |                                                                             | 4       |

Table 3: Intervention strategies to promote AFU.

| Major Category                          | Interventions                                                                 | Studies |
|-----------------------------------------|-----------------------------------------------------------------------------|---------|
| 1. Patient and Family Support Management| Patient education (workshops, informational materials and telephone and in-person counseling) | 12      |
|                                        | Support network enhancement                                                 | 9       |
|                                        | Transportation assistance                                                   | 5       |
|                                        | Case management                                                             | 2       |
| Total                                   |                                                                             | 28      |
| 2. Information System and Interaction Improvement| Improve clinician reminders (short message service, electronic mail, telephone and paper record) | 39      |
|                                        | Delivery system design                                                     | 8       |
|                                        | Promote positive collaborative relationships                                 | 9       |
| Total                                   |                                                                             | 56      |
| 3. Research Design Enhancement          | Pre-randomization ("run in" and "testing")                                 | 2       |
|                                        | Active control strategy                                                     | 2       |
|                                        | Develop a reasonable regimen protocol                                       | 11      |
| Total                                   |                                                                             | 15      |
or outcome. Lin Ailing [22], conducted a trial to analyze AFU and factors that influence AFU in elderly arrhythmic patients implanted with a cardiac pacemaker. Each enrolled patient received a follow-up evaluation by a questionnaire composed of the following 4 questions: (1) Can you attend regular clinic visits according to the follow-up plan? (2) Can you make self-surveillance on your pulse under medical instructions? (3) Can you come back to the clinic on the occurrence of an abnormal pulse rhythm? And (4) Can you accept long-term follow-up by medical staff? "Good compliance" was only reported when 4 answers of "completely yes" were received; otherwise, the patient was considered to be in "bad compliance". Another trial investigated clinical AFU after endoscopic sinus surgery in patients with chronic rhinosinusitis [23]; the postoperative effect "good compliance" referred to the postoperative patients who adhered to clinical follow-up for at least 6 months and 5 times; otherwise, the patients were considered to be in "bad compliance".

Improved awareness of the five factors associated with AFU will aid in the selection of priority objectives and will guide interventions. In addition to improving AFU, this knowledge will eventually improve the quality of clinical research. The first factor, the relationship between individual patient characteristics and AFU, has received increased attention and is the most important. In the subcategory analysis, a representative study concerning follow-up for abnormal Papanicolaou tests indicated that young age, minority race and low socioeconomic status were risk factors for non-adherence to recommendations [24]. The second major factor was social support, which helps patients reduce negative attitudes toward treatment and motivates patients to remember to implement the treatment. Studies also showed that patients who had emotional support and help from family members, friends or healthcare providers were more likely to comply with the treatment [25]. Interestingly, issues of cultural context, social support (instrumental and emotional) and related social network factors have also been found to enhance and to reduce Papanicolaou and mammography test AFU among African American and Hispanic women [26-28]. However, inconsistent evidence may reflect differences in measurement or personal preferences that affect the appointment scheduling decision. Studies have also explored selected physician factors and their relationship to follow-up after abnormal results. The importance of communication between patients and physicians regarding risk, medication choice, results and necessary follow-up was frequently noted [29]. Wolf illustrated the complexity of communication tasks, such as describing the procedure, advance preparation, benefits and risks, and demonstrated that physician self-reporting of the completion of these tasks was significantly higher than was observed in a separate video sample [30]. However, few studies have actually assessed the completion of communication regarding the discrete steps that are necessary for follow-up. The complexity of this communication, not only with the patient but also between providers at other locations, reinforces the importance of focusing on steps that would enhance a successful transition. These steps include transparency of the informed consent document; a strong relationship among the study coordinator, care providers and participants; and consistency in protocols for maintaining contact with participants to decrease patient attrition [31]. Physician decision-making and failure to refer for further testing can contribute to follow-up failure [32,33]. This failure may be due to a physician being unaware of an abnormal test result or choosing not to refer. Physicians' lack of adherence to follow-up guidelines has also been described and has been noted in diagnostic follow-up after fecal occult blood test screening in the elderly [34]. Other provider-related characteristics include board certification, years in practice, specialty, perceptions of severity gender and staff sensitivity [26,27]. Additional factors that may increase the likelihood of attrition include a large number of follow-up tests and study designs with control groups that receive no perceived benefit. Some participants have withdrawn from studies following the intervention phase because they are no longer provided with therapies even though study visits continue to occur [17]. Reminder systems for providers and for patients (mail and phone) have been frequently and consistently cited as being significantly beneficial, as have other information tracking systems [35]. In several studies, organizational structural characteristics, such as waiting times and the presence of on-site specialists and tracking technology, have demonstrated a positive relationship with AFU [35]. Several studies discussed a growing interest in the relationship between case managers or navigators and adherence, including the impact on the prevalence of follow-up after abnormal tests. Navigators may essentially tailor intervention [36]. Another important factor in relation to AFU is public policy and federal initiatives [37]. Given the importance of insurance, including the benefit structure within insurance policies [38], public policies impact follow-up by enabling patients to access and receive testing. Professional norms have been influenced by the promulgation of evidence-based guidelines for breast, cervical and colorectal cancer screening [39]. These norms include evidence-based guidelines for follow-up diagnosis [40,41]. Quality expectations and benchmarks, such as the Healthcare Effectiveness Data and Information Set, have been shown to influence health plan and provider performance in screening [42].

A comprehensive understanding of the multiple related factors of AFU and their associated interfaces provides a foundation for improving interventions. The present study has also shown that three intervention strategies can improve follow-up, although the mechanisms of action are unclear. The first category of strategies is patient and family support management. Studies addressing patient self-management emphasized the importance of patient education in various ways [26,35]. Several of these studies reported a guiding theoretical model or framework. The interventions were usually designed to address several patient-level characteristics that were mentioned above, including knowledge deficits, fears, forgetfulness, family member support and other support networks that promote patient involvement in research; family therapy referral was also considered [43]. The second category of strategies, which is the most important, is information system and interaction improvement. Studies of interventions to improve clinician reminders have shown significant and consistent effectiveness for almost all of the study types. Reminders can especially be used to modify the behavior of unintentionally non-adherent patients [44]. Such systems can cue the physician and remind the patients about the recommended follow-up visits and abnormal test or diagnostic evaluations. Additionally, reminder systems can provide positive feedback for the regimen and AFU. Delivery system design strategies have been shown to directly affect the performance of follow-up testing and include the implementation of same-day and same-site testing, as these
strategies eliminate interfaces with other organizations, repeat visits to the study site and the process of appointment scheduling [45]. To promote positive, collaborative relationships between subjects and members of the research team, one person can be chosen as the primary contact for the study participants; this contact can cross-train all of the personnel so that they will be knowledgeable about the ongoing trials and properly respond to participant needs [14]. The last category of strategies was research design enhancement. A preventative approach for promoting adherence in effectiveness studies is recruitment screening to identify potential subjects at risk for compromised adherence. Recruitment screening requires excluding subjects who are at-risk for non-adherence by identifying histories of poor treatment adherence, inconsistencies with medical care (e.g., lateness or missed appointments) and problems with communication or ambivalence about participating. This preventative approach also includes effective communication about trial participation (e.g., explanation of informed consent, acceptance of random allocation and importance of adherence) [46]. For the “active control” strategy, a Neuro rehabilitation trial provided an alternative to participant remuneration; the alternative provided participants with the potential to derive a perceived benefit from study participation, even if they were not in the experimental group [14]. It must be emphasized that to develop a reasonable regimen protocol, the following 4 steps should be considered [16]: 1. Set goals with clear and realistic expectations; 2. Streamline the protocol to consider the minimum dosing frequency, number of pills and risk of side effects, as well as available materials and convenient packaging; 3. Develop a regimen that can be realistically integrated with patients’ other daily activities; and 4. Enhance healthcare access by promoting comorbid condition treatment and addressing psychosocial factors.

The interpretation of the current study must be understood within the context of its strengths and limitations. The strengths of the study included that the broad range of content concerning the AFU spectrum gave a comprehensive understanding of measurement methods, associated factors and intervention strategies. Meanwhile, despite the descriptive character of the study, the relative strict eligible criteria requiring clear calculation method for measurement, specific data to indicate direction and magnitude of associated factors or intervention strategies improved methodological rigor and validity of this study. The weaknesses of the study must also be acknowledged. The huge variety in study design and multifold complexity made it impossible for a meta-analysis to quantitatively analyze the direction and magnitude of intervention effects. Despite these limitations, this study remains the first ever study to systematically assess the AFU in clinical research spectrum, evaluating the measurement methods used in previous studies, identifying influencing factors associated with AFU and exploring effective intervention improvements.

In conclusion, our study has demonstrated that the number of published studies regarding the measurement, associated factors and intervention strategies of AFU is increasing. The aim of these studies is to illuminate the nature of patient adherence to clinical research across a broad spectrum of patient conditions and improvement interventions. We also found that the majority of studies used different FURs to calculate AFU, that individual patient characteristics were the most important AFU-associated factor and that information system and interaction improvement was the most studied intervention strategy to improve AFU. Therefore, individual patient-centered information system and interaction improvement would be the most important direction of development to improve patient AFU, while, multiaspect environment factors and research design enhancement should be paid more attention. A full understanding of the measurements, associated factors and intervention strategies of AFU is an important step toward improving the quality of clinical research.

Acknowledgements

This study was supported by Ministry of Science and Technology of China grants (973 program, 2015CB964600), the Pearl River Science and Technology New Star (Grant No. 2014J2200060) Project of Guangzhou City, the Guangdong Provincial Natural Science Foundation for Distinguished Young Scholars of China (Grant No. 2014A030306030), Youth Science and Technology Innovation Talents Fund for Special of High-Level Talents in Guangdong Province (Grant No. 2014TQ01R573), the Cultivation Projects (12ykpy61) and Intensive Cultivation Projects (2015ykzd11) for Young Teaching Staff at Sun Yat-sen University from the Fundamental Research Funds for the Central Universities and the Fundamental Research Funds of the State Key Laboratory of Ophthalmology (Grant No. 2015QN01). The study’s sponsors played no role in the study protocol design, data collection, data analysis, data interpretation, manuscript preparation, or the decision to submit the manuscript for publication.

References

1. Chen XZ, Yang K, Zhang YC (2008) The Strategy of Follow-up Project in Surgical Oncology. Medicine and physiology 4:6.
2. Isaaz K, Mayaud N, Gerbay A, Sabry MH, Richard L, et al. (2013) Long-term clinical outcome and routine angiographic follow-up after successful recanalization of complex coronary true chronic total occlusion with a long stent length: a single-center experience. J Invasive Cardiol 25: 323-329.
3. Wu Y, Su J, Fu L (2012) Compliance of Felten-Based Follow-up in Patients with Chronic Kidney Disease. Chinese General Practise 1198-1200.
4. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS (2007) Management of hepatitis B: summary of a clinical research workshop. Hepatology 45: 1056-1075.
5. Schwartz GF (2005) Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 16: 114-121.
6. Ma RH, Wang YJ, Wang CX, Zhao XQ, Wang YL, et al. (2008) A survey on cerebral infarction/transient ischemic attack inpatients compliance with secondary stroke prevention and follow-up 90 days. Zhonghua Yi Xue Za Zhi 88: 2618-2622.
7. Hertz RP, Unger AN, Lustik MB (2005) Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 27: 1084-1073.
8. Baren JM, Boudreaux ED, Brenner BE, Cuddyka RK, Rowe BH, et al. (2006) Randomized controlled trial of emergency department interventions to improve primary care follow-up for patients with acute asthma. Chest 129: 257-265.
9. Ho M, Garnett SP, Baur LA, Burrows T, Stewart L, et al. (2013) Impact of dietary and exercise interventions on weight change and metabolic outcomes in obese children and adolescents: a systematic review and meta-analysis of randomized trials. JAMA Pediatr 167: 759-768.

Citation: Wu X, Lin H (2015) Patient Adherence to Follow-Up in Clinical Research: A Systematic Review of Measurements, Associated Factors and Intervention Strategies. J Clin Res Ophthalmol 2(4): 058-064. DOI: 10.17352/2455-1414.000023
10. Chen YT, Cao JH, Li YN, Liang GT (2013) Logistic regression analysis on influence factors of chronic sinusitis after endoscopic sinus surgery. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 48: 511-513.

11. Huang G, Crooms R, Chen Q, Congdon N, He M (2012) Compliance with follow-up after cataract surgery in rural China. Ophthalmic Epidemiol 19: 67-73.

12. Iurriaga H, Zanollı M, Damm C, Oporto J, Acuna O, et al. (2012) Frequent Evaluation To Improve Compliance In Patients Treated With Occlusion For Amblyopia: A Randomized controlled Trial. Binocul Vis Strabolog Q Simms Romano 27: 195-204.

13. Toenders W (1992) Patient compliance in medical practice and clinical trials. Int J Risk Saf Med 3: 338.

14. Page SJ, Persch AC (2013) Recruitment, retention, and blinding in clinical trials. Am J Occup Ther 67: 154-161.

15. Lin H, Wu X (2014) Intervention strategies for improving patient adherence to follow-up in the era of mobile information technology: a systematic review and meta-analysis. PLoS One 9: e104266.

16. Robiner WN (2005) Enhancing adherence in clinical research. Contemp Clin Trials 26: 59-77.

17. Cooley ME, Sarna L, Brown JK, Williams RD, Chernecky C, et al. (2003) Challenges of recruitment and retention in multisite clinical research. Cancer Nurs 26: 376-384.

18. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, et al. (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351: 2683-2693.

19. Mahtani KR, Heneghan CJ, Glasziou PP, Perera R (2011) Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database Syst Rev CD005025.

20. Myers RE, Turner B, Weinberg D, Hauck WW, Hyslop T, et al. (2001) Complete diagnostic evaluation in colorectal cancer screening: research design and baseline findings. Prev Med 33: 249-260.

21. Budaus L, Huland H, Graefen M (2012) Controversies in the management of localized prostate cancer: radical prostatectomy still the standard of care. Crit Rev Oncol Hematol 84: e24-29.

22. Lin AL, Liao MF (2011) Analysis of the dependence of the follow-up in 90 cases of elderly patients planted cardiac pacemaker. Public Medical Forum Magazine 4-5.

23. Huang HY, He HS, Xu O, Wang YX, Duan NC, et al. (2013) Analysis of clinic evaluation To Improve Compliance In Patients Treated With Occlusion For Amblyopia. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 48: 511-513.

24. Khanna N, Phillips MD. (2001) Adherence to care plan in women with abnormal Papanicolaou smears: a review of barriers and interventions. J Am Board Fam Pract 14: 123-130.

25. Voits CI, Steffens DC, Flint EP, Bosworth HB (2005) Social support and locus of control as predictors of adherence to antidepressant medication in an elderly population. Am J Geriatr Psychiatry 13: 157-165.

26. Yabroff KR, Washington KS, Leader A, Neilson E, Mandelblatt J (2003) is the promise of cancer-screening programs being compromised? Quality of follow-up care after abnormal screening results. Med Care Res Rev 60: 294-331.

27. Abercrombie PD (2001) Improving adherence to abnormal Pap smear follow-up. J Obstet Gynecol Neonatal Nurs 30: 80-88.

28. McKee D (1997) Improving the follow-up of patients with abnormal Papanicolaou smear results. Arch Fam Med 6: 574-577.

29. Schofield PE, Butow PN (2004) Towards better communication in cancer care: a framework for developing evidence-based interventions. Patient Educ Couns 55: 32-39.

30. Wolf MS, Baker DW, Makoul G (2007) Physician-patient communication about colorectal cancer screening. J Gen Intern Med 22: 1493-1499.

31. Bedlack RS, Cudkowicz ME (2009) Clinical trials in progressive neurological diseases. Recruitment, enrollment, retention and compliance. Front Neurol Neurosci 25: 144-151.

32. Jimbo M, Myers RE, Meyer B, Hyslop T, Coccof J, et al. (2009) Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Ann Fam Med 7: 11-16.

33. Fisher DA, Jeffreys A, Coffman CJ, Fasanella K (2006) Barriers to full colon evaluation for a positive fecal occult blood test. Cancer Epidemiol Biomarkers Prev 15: 1232-1235.

34. Nadel MR, Shapiro JA, Klabunde CN, Steeff LC, Uhler R, et al. (2005) A national survey of primary care physicians’ methods for screening for fecal occult blood. Ann Intern Med 142: 86-94.

35. Eggelston KS, Coker AL, Das IP, Cordray ST, Luchok KJ (2007) Understanding barriers for adherence to follow-up care for abnormal pap tests. J Womens Health (Larchmt) 16: 311-330.

36. Masi CM, Blackman DJ, Peek ME (2007) Interventions to enhance breast cancer screening, diagnosis, and treatment among racial and ethnic minority women. Med Care Res Rev 64: 195S-242S.

37. Colditz GA, Samplin-Salgado M, Ryan CT, Dart H, Fisher L, et al. (2002) Harvard report on cancer prevention, volume 5: fulfilling the potential for cancer prevention: policy approaches. Cancer Causes Control 13: 199-212.

38. Friedman C, Ahmed F, Fraanks A, Weatherup T, Manning M, et al. (2002) Association between health insurance coverage of office visit and cancer screening among women. Med Care 40: 1060-1067.

39. Woolf SH (2008) The meaning of translational research and why it matters. JAMA 299: 211-213.

40. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, et al. (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology134: 1570-1595.

41. Winawer S, Fletcher R, Rex D, Bond J, Burt R, et al. (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 124: 544-560.

42. Saffaty M, Myers RE (2008) The effect of HEDIS measurement of colorectal cancer screening on insurance plans in Pennsylvania. Am J Manag Care 14: 277-282.

43. Roter DL, Hall JA, Mirisca R, Nordstrom R, Crelin D, et al. (1998) Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 36: 1139-1161.

44. Vervoort M, Linn AJ, van Weert JC, de Bakker DH, Bouvy ML, et al. (2012) The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. J Am Med Inform Assoc 19: 696-704.

45. Yabroff KR, Kerner JF, Mandelblatt JS (2000) Effectiveness of interventions to improve follow-up after abnormal cervical cancer screening. Prev Med 31: 429-439.

46. Martin KA, Bowen DJ, Dunbar-Jacob J, Perri MG (2000) Who will adhere? Key issues in the study and prediction of adherence in randomized controlled trials. Control Clin Trials 21: 195S-1995.